TY - JOUR
T1 - The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders
T2 - Update 2009 on the treatment of acute mania
AU - WFSBP Task Force On Treatment Guidelines For Bipolar Disorders
AU - Grunze, Heinz
AU - Vieta, Eduard
AU - Goodwin, Guy M.
AU - Bowden, Charles
AU - Licht, Rasmus W.
AU - Mller, Hans Jürgen
AU - Kasper, Siegfried
AU - Grunze, Heinz
AU - Moller, Hans Jurgen
AU - Vieta, Eduard
AU - Akiskal, Hagop
AU - Ayuso-Gutierrez, Jose Luis
AU - Bauer, Michael
AU - Bech, Per
AU - Berk, Michael
AU - Bitter, Istvan
AU - Burrows, Graham
AU - Calabrese, Joseph
AU - Cassano, Giovanni
AU - Cetkovich-Bakmas, Marcelo
AU - Cookson, John C.
AU - Ferrier, I. Nicol
AU - Gattaz, Wagner F.
AU - Goodwin, Frederik K.
AU - Heinze, Gerhard
AU - Higuchi, Teruhiko
AU - Hirschfeld, Robert M.
AU - Hoeschl, Cyril
AU - Holsboer-Trachsler, Edith
AU - Jamison, Kay Redfield
AU - Katona, Cornelius
AU - Keller, Martin
AU - Kostukova, E.
AU - Kruger, Hever
AU - Kulhara, Parmanand
AU - Lecruibier, Yves
AU - Larach, Veronica
AU - Lingjaerde, Odd
AU - Lublin, Henrik
AU - Maj, Mario
AU - Mendlewicz, Julien
AU - Camacho, Roberto Miranda
AU - Mitchell, Philip
AU - Mosolov, S.
AU - Montgomery, Stuart
AU - Nemeroff, Charles
AU - Nolen, Willem
AU - Paykel, Eugene S.
AU - Post, Robert M.
AU - Puzynski, Stanislaw
N1 - Funding Information:
Charles Bowden received grants/research support, consulting fees and honoraria within the last 3 years from Abbott Laboratories, Astra Zeneca, Bristol-Myers Squibb, Elan Pharmaceuticals, GlaxoSmithK-line, Janssen, Lilly Research, National Institute of Mental Health, Parke Davis, Pfizer, R.W. Johnson Pharmaceutical Institute, Sanofi Synthelabo, Smith Kline Beecham, Stanley Medical Research Foundation and UCB Pharma, Inc.
PY - 2009/1/1
Y1 - 2009/1/1
N2 - These updated guidelines are based on a first edition that was published in 2003, and have been edited and updated with the available scientific evidence until end of 2008. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute mania in adults. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific evidence was finally asigned different grades of recommendation to ensure practicability.
AB - These updated guidelines are based on a first edition that was published in 2003, and have been edited and updated with the available scientific evidence until end of 2008. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute mania in adults. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific evidence was finally asigned different grades of recommendation to ensure practicability.
KW - Acute treatment
KW - Antipsychotics
KW - Bipolar disorder
KW - Depression
KW - Electroconvulsive therapy
KW - Evidence-based guidelines
KW - Mania
KW - Mood stabiliser
KW - Pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=67650134119&partnerID=8YFLogxK
U2 - 10.1080/15622970902823202
DO - 10.1080/15622970902823202
M3 - Review article
C2 - 19347775
AN - SCOPUS:67650134119
SN - 1562-2975
VL - 10
SP - 85
EP - 116
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 2
ER -
